

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2004

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-12957	22-2372868
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

685 Route 202/206, Bridgewater, New Jersey 08807
(Address of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code: (908) 541-8600

(Former name or former address, if changed since last report)

Item 5.02 Departure of Directors or Principle Officers; Election of Director
Election of Directors

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Dr. Goran Ando and Mr. Victor P. Micati have been appointed to the Company's Board of Directors.

Dr. Ando brings over 25 years of industry experience to Enzon. Since April 2003, he has served as Chief Executive Officer of Celltech Group plc (LSE: CCH; NYSE: CLL), one of Europe's largest biotechnology companies. Prior to joining Celltech in April 2003, Dr. Ando served in various senior R&D posts at Pharmacia Corporation. In his most recent role at Pharmacia, Dr. Ando was Executive Vice President and President of R&D and also had executive responsibilities for manufacturing and business development.

Prior to his most recent role with Pharmacia, Dr. Ando held various executive positions including, Executive Vice President & Deputy Chief Executive Officer, Pharmacia AB, Sweden; Executive Vice President, Worldwide Science & Technology, Pharmacia & Upjohn, UK; and Chairman, Pharmacia & Upjohn AB, Sweden. Prior to joining Pharmacia, Dr. Ando held various senior posts with Glaxo Ltd., Bristol Myers International Group, and Pfizer International. Dr. Ando received his M.D. from Linkoping University in Sweden and currently sits on the board of the BioIndustry Association in the UK.

Mr. Micati is a retired senior executive of Pfizer Inc. (NYSE: PFE) and brings nearly 40 years of pharmaceutical experience to Enzon. In 1999, Mr. Micati retired from Pfizer where he most recently served as Executive Vice President of the Pharmaceutical Group of Pfizer and Vice President of Pfizer Inc. In this capacity, Mr. Micati was responsible for Pfizer's European pharmaceutical operations and its global consumer healthcare business. At the time of his retirement, Mr. Micati was also a member of the 10-person corporate management committee responsible for all aspects of Pfizer's global operations.

Mr. Micati first joined Pfizer in 1965 and over a distinguished 34-year career served in numerous capacities, including: President of European Operations; Executive Vice President of Pfizer Europe; Senior Vice President, Pharmaceuticals; Vice President of Pharmaceutical Development, Pfizer International; and Vice President of Marketing, Pfizer Laboratories. Mr. Micati also served as a member of the Pfizer International Board of Directors. Mr. Micati graduated from Middlebury College with a B.A. in chemistry in 1962 and earned an M.B.A. in marketing from Columbia University in 1965. Mr. Micati is currently a consultant to the pharmaceutical industry. He is a director of Ilex Oncology (Nasdaq: ILXO) and a member of the Advisory Board of Almirall, a

Spanish pharmaceutical company.

Resignation of Arthur J. Higgins

Enzon Pharmaceuticals today also announced that Arthur J. Higgins will step down from the Company's Board of Directors effective December 7, 2004. Mr. Higgins has been a director of Enzon since May 2001 and served as Chairman of Enzon's Board of Directors from December 2001 to September 2004. Mr. Higgins served as Enzon's President and Chief Executive Officer from May 2001 until he assumed the leadership of Bayer HealthCare in May 2004.

Item 9.01 Financial Statements and Exhibits

Exhibit 99.1 Press Release dated November 15, 2004

Exhibit 99.2 Press Release dated November 15, 2004

Exhibit 99.3 Press Release dated November 15, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 15, 2004

By: /s/ Kenneth J. Zuerblis

Kenneth J. Zuerblis
Vice President, Finance and
Chief Financial Officer

ENZON
PHARMACEUTICALS

For Immediate Release

PRESS RELEASE

Contact: Susan M. Mesco
Director, Investor Relations
(908)541-8777

Euro RSCG Life NRP
Mark R. Vincent, Media Relations
(212)845-4239

DR. GORAN ANDO JOINS ENZON'S BOARD OF DIRECTORS

Bridgewater, NJ - November 15, 2004 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Dr. Goran Ando has been appointed to the Company's Board of Directors.

Dr. Ando brings over 25 years of industry experience to Enzon. Since April 2003, he has served as Chief Executive Officer of Celltech Group plc (LSE: CCH; NYSE: CLL), one of Europe's largest biotechnology companies. Prior to joining Celltech in April 2003, Dr. Ando served in various senior R&D posts at Pharmacia Corporation. In his most recent role at Pharmacia, Dr. Ando was Executive Vice President and President of R&D and also had executive responsibilities for manufacturing and business development. Prior to his most recent role with Pharmacia, Dr. Ando held various executive positions including, Executive Vice President & Deputy Chief Executive Officer, Pharmacia AB, Sweden; Executive Vice President, Worldwide Science & Technology, Pharmacia & Upjohn, UK; and Chairman, Pharmacia & Upjohn AB, Sweden. Prior to joining Pharmacia, Dr. Ando held various senior posts with Glaxo Ltd., Bristol Myers International Group, and Pfizer International.

Dr. Ando received his M.D. from Linkoping University in Sweden and currently sits on the board of the BioIndustry Association in the UK.

"We are exceptionally pleased to have Dr. Goran Ando join Enzon's Board of Directors," said Jeffrey H. Buchalter, non-executive chairman of Enzon's board of directors. "His extensive industry experience and successful track record in the discovery and development of pharmaceuticals will be of tremendous strategic value to Enzon."

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R))

-more-

685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>

technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Enzon has several drug candidates in various stages of development, independently and with partners, including MARQIBO(R) (formerly referred to as Onco TCS), for which a U.S. marketing application is currently being reviewed by the FDA for the treatment of relapsed aggressive non-Hodgkin's lymphoma. Further information about Enzon and this press release

can be found on the Company's web site at www.enzon.com.

The forward-looking statement contained herein is not based on historical fact, but on expectations regarding the future. The statement is subject to known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments discussed above. Such factors include those described in Enzon's Form 10-K and Forms 10-Q on file with the SEC. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information in this press release is as of November 15, 2004 and the Company undertakes no duty to update this information.

#

=====
685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>

ENZON
PHARMACEUTICALS

For Immediate Release

PRESS RELEASE

Contact: Susan M. Mesco
Director, Investor Relations
(908) 541-8777

Euro RSCG Life NRP
Mark R. Vincent, Media Relations
(212) 845-4239

VICTOR P. MICATI JOINS ENZON'S BOARD OF DIRECTORS

Bridgewater, NJ - November 15, 2004 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Victor P. Micati has been appointed to the Company's Board of Directors. Mr. Micati is a retired senior executive of Pfizer Inc. (NYSE: PFE) and brings nearly 40 years of pharmaceutical experience to Enzon.

In 1999, Mr. Micati retired from Pfizer where he most recently served as Executive Vice President of the Pharmaceutical Group of Pfizer and Vice President of Pfizer Inc. In this capacity, Mr. Micati was responsible for Pfizer's European pharmaceutical operations and its global consumer healthcare business. At the time of his retirement, Mr. Micati was also a member of the 10-person corporate management committee responsible for all aspects of Pfizer's global operations.

Mr. Micati first joined Pfizer in 1965 and over a distinguished 34-year career served in numerous capacities, including: President of European Operations; Executive Vice President of Pfizer Europe; Senior Vice President, Pharmaceuticals; Vice President of Pharmaceutical Development, Pfizer International; and Vice President of Marketing, Pfizer Laboratories. Mr. Micati also served as a member of the Pfizer International Board of Directors.

Mr. Micati graduated from Middlebury College with a B.A. in chemistry in 1962 and earned an M.B.A. in marketing from Columbia University in 1965. Mr. Micati is currently a consultant to the pharmaceutical industry. He is a director of Ilex Oncology (Nasdaq: ILXO) and a member of the Advisory Board of Almirall, a Spanish pharmaceutical company.

"We are very fortunate to have an executive of Vic Micati's caliber join our Board," said Jeffrey H. Buchalter, non-executive chairman of Enzon's board of directors. "Mr. Micati brings an impressive set of credentials to Enzon, including his experience as a member of the management team responsible for global operations of the world's largest pharmaceutical company. His valuable strategic insight will prove to be a significant asset as we continue to identify both near- and long-term growth opportunities for Enzon."

-more-

685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>

Enzon Board/Page 2

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are

complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Enzon has several drug candidates in various stages of development, independently and with partners, including MARQIBO(R) (formerly referred to as Onco TCS), for which a U.S. marketing application is currently being reviewed by the FDA for the treatment of relapsed aggressive non-Hodgkin's lymphoma. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

The forward-looking statement contained herein is not based on historical fact, but on expectations regarding the future. The statement is subject to known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments discussed above. Such factors include those described in Enzon's Form 10-K and Forms 10-Q on file with the SEC. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information in this press release is as of November 15, 2004 and the Company undertakes no duty to update this information.

#

=====
685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>

ENZON
PHARMACEUTICALS

For Immediate Release

PRESS RELEASE

Contact: Susan M. Mesco
Director, Investor Relations
(908) 541-8777

Euro RSCG Life NRP
Mark R. Vincent, Media Relations
(212) 845-4239

ARTHUR J. HIGGINS TO STEP DOWN FROM ENZON'S BOARD OF DIRECTORS

Bridgewater, NJ - November 15, 2004 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Arthur J. Higgins will step down from the Company's Board of Directors effective December 7, 2004. Mr. Higgins has been a director of Enzon since May 2001 and served as Chairman of Enzon's Board of Directors from December 2001 to September 2004. Mr. Higgins served as Enzon's President and Chief Executive Officer from May 2001 until he assumed the leadership of Bayer HealthCare in May 2004.

"On behalf of the directors and employees of Enzon, I would like to thank Arthur for his significant contributions to the Company, both as a director and as the Company's Chairman and Chief Executive Officer," said Jeffrey H. Buchalter, non-executive chairman of Enzon's board of directors. "Arthur led Enzon's transition into a fully integrated biopharmaceutical company through the execution of select transactions. While we will miss Arthur's contributions and strategic value, we do understand the demands of his current position and wish him the very best in the future."

Mr. Higgins commented, "I have thoroughly enjoyed my time with Enzon and the success we attained in just three short years. I am confident that Enzon's forward progression will continue and I wish the Company the best as it continues on its strategic path to build a leading biopharmaceutical company."

Today Enzon also announced that Victor P. Micati and Dr. Goran Ando have been appointed to the Company's Board of Directors. Mr. Micati is a retired senior executive of Pfizer Inc. (NYSE: PFE) and Dr. Ando is currently serving as Chief Executive Officer of Celltech Group plc (LSE: CCH; NYSE: CLL). Please refer to Company's press releases issued today for additional details.

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in

-more-

685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>

North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Enzon has several drug candidates in various stages of development, independently and with partners, including MARQIBO(R) (formerly referred to as Onco TCS), for which a U.S. marketing application is currently being reviewed by the FDA for the treatment of relapsed aggressive non-Hodgkin's lymphoma. Further information

about Enzon and this press release can be found on the Company's web site at www.enzon.com.

The forward-looking statement contained herein is not based on historical fact, but on expectations regarding the future. The statement is subject to known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments discussed above. Such factors include those described in Enzon's Form 10-K and Forms 10-Q on file with the SEC. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. All information in this press release is as of November 15, 2004 and the Company undertakes no duty to update this information.

#

=====
685 Route 202/206 Bridgewater, NJ 08807
Phone: (908) 541-8600 Fax: (908) 575-9457
<http://www.enzon.com>